World Asset Management Inc Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)
World Asset Management Inc grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,332 shares of the medical research company’s stock after purchasing an additional 104 shares during the quarter. World Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $3,679,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its position in shares of Thermo Fisher Scientific by 7.1% during the 2nd quarter. BlackRock Inc. now owns 28,955,941 shares of the medical research company’s stock valued at $10,491,896,000 after purchasing an additional 1,929,802 shares during the last quarter. State Street Corp increased its holdings in Thermo Fisher Scientific by 1.0% in the 1st quarter. State Street Corp now owns 16,503,764 shares of the medical research company’s stock worth $4,684,029,000 after acquiring an additional 165,895 shares during the last quarter. FMR LLC increased its holdings in Thermo Fisher Scientific by 3.3% in the 2nd quarter. FMR LLC now owns 11,621,011 shares of the medical research company’s stock worth $4,210,756,000 after acquiring an additional 376,531 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Thermo Fisher Scientific by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,469,372 shares of the medical research company’s stock worth $1,257,091,000 after acquiring an additional 22,856 shares during the last quarter. Finally, Copper Rock Capital Partners LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $265,775,000. 88.12% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have weighed in on TMO. Atlantic Securities began coverage on Thermo Fisher Scientific in a report on Wednesday, September 30th. They set an “overweight” rating and a $494.00 target price for the company. Credit Suisse Group lifted their target price on Thermo Fisher Scientific from $432.00 to $488.00 and gave the company a “neutral” rating in a report on Thursday. Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $468.00 to $477.00 and gave the company a “buy” rating in a report on Thursday, September 17th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $485.00 to $535.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Stifel Nicolaus lifted their target price on Thermo Fisher Scientific from $370.00 to $460.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Two equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $472.40.
NYSE:TMO traded down $1.82 during mid-day trading on Friday, reaching $480.17. The stock had a trading volume of 1,164,433 shares, compared to its average volume of 1,065,173. The firm has a 50 day moving average price of $439.48 and a two-hundred day moving average price of $384.86. The stock has a market capitalization of $189.95 billion, a P/E ratio of 51.97, a P/E/G ratio of 1.86 and a beta of 0.98. Thermo Fisher Scientific Inc. has a one year low of $250.21 and a one year high of $485.00. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.02 and a current ratio of 2.62.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 21st. The medical research company reported $5.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.37 by $1.26. The company had revenue of $8.25 billion during the quarter, compared to the consensus estimate of $7.68 billion. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. Thermo Fisher Scientific’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 15.99 earnings per share for the current year.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
Read More: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.